Although further investigation is needed, OBP-702 can be a promising treatment option for pancreatic cancer as an immunostimulant that can convert the tumor microenvironment immunologically from cold to hot following strong direct cytotoxic activity and provide durable anti-tumor effects through activation of long-lived memory CD8 + T cells, leading to a sustained survival benefit for pancreatic cancer patients. The gene discussed is CD8A; the disease is neoplasm.